Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study
- PMID: 16368305
- DOI: 10.1016/j.ahj.2005.10.006
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study
Abstract
Background: Coronary atherosclerosis includes an activation of circulating T lymphocytes. Statins exert anti-inflammatory effects beyond lipid lowering. Whether these properties influence systemic T lymphocytes is unclear.
Methods: To investigate the effect of atorvastatin on circulating T-lymphocyte subsets producing proinflammatory and anti-inflammatory cytokines (interferon gamma [IFN-gamma(+)], interleukin 2 [IL-2(+)], IL-4(+), and IL-10(+)) and on the T-cell-activating soluble CD40 ligand (sCD40L), 30 hypercholesterolemic patients with angiographically documented stable coronary artery disease (CAD) were randomized to placebo or atorvastatin (20 mg/d) for 3 months. Eight healthy volunteers served as controls. Levels of peripheral cytokine-producing CD4+ and CD8+ T cells and their CD28- subsets were determined by FACS. Serum soluble CD40L was measured with ELISA.
Results: IL-2(+) T lymphocytes and sCD40L levels were higher in patients with CAD compared with controls, whereas IFN-gamma(+) and anti-inflammatory IL-4(+) and IL-10(+) T lymphocytes were similar. Levels of IL-2(+), IFN-gamma(+), IL-4(+), and IL-10(+) T-cell subsets as well as CD28- T lymphocytes were neither changed by atorvastatin nor by placebo, whereas sCD40L was lowered only in atorvastatin-treated patients (P < .01).
Conclusion: Circulating IL-2(+) T lymphocytes are increased in patients with stable CAD reflecting an activation of the global immune system, but are not influenced by atorvastatin therapy. The elevated levels of platelet-derived T-lymphocyte-stimulating sCD40L are decreased by atorvastatin probably reflecting an atheroprotective effect. Hence, sCD40L may be an additional biomarker to be considered when evaluating the treatment effects of statins in patients with stable CAD.
Similar articles
-
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).Am J Cardiol. 2005 Sep 5;96(5A):39F-44F. doi: 10.1016/j.amjcard.2005.06.025. Am J Cardiol. 2005. PMID: 16126022 Review.
-
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.Circulation. 2005 Feb 1;111(4):412-9. doi: 10.1161/01.CIR.0000153810.81187.7D. Circulation. 2005. PMID: 15687128 Clinical Trial.
-
CD40 ligand: a novel target in the fight against cardiovascular disease.Ann Pharmacother. 2004 Sep;38(9):1500-8. doi: 10.1345/aph.1D611. Epub 2004 Jul 27. Ann Pharmacother. 2004. PMID: 15280513 Review.
-
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.Circulation. 2004 Jul 27;110(4):386-91. doi: 10.1161/01.CIR.0000136588.62638.5E. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262833 Clinical Trial.
-
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.Circulation. 2004 Apr 27;109(16):1966-72. doi: 10.1161/01.CIR.0000125700.33637.B1. Epub 2004 Mar 29. Circulation. 2004. PMID: 15051633 Clinical Trial.
Cited by
-
Impact of Physical Exercise on Platelets: Focus on Its Effects in Metabolic Chronic Diseases.Antioxidants (Basel). 2023 Aug 14;12(8):1609. doi: 10.3390/antiox12081609. Antioxidants (Basel). 2023. PMID: 37627603 Free PMC article. Review.
-
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell.Int J Mol Sci. 2022 Sep 28;23(19):11446. doi: 10.3390/ijms231911446. Int J Mol Sci. 2022. PMID: 36232746 Free PMC article. Review.
-
Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease.Small GTPases. 2021 Sep-Nov;12(5-6):440-457. doi: 10.1080/21541248.2021.1878001. Epub 2021 Apr 12. Small GTPases. 2021. PMID: 33459160 Free PMC article. Review.
-
Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.JCI Insight. 2019 Nov 1;4(21):e131530. doi: 10.1172/jci.insight.131530. JCI Insight. 2019. PMID: 31573980 Free PMC article.
-
On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells.Immunol Res. 2019 Oct;67(4-5):310-324. doi: 10.1007/s12026-019-09089-5. Immunol Res. 2019. PMID: 31399952 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous